The Central Drugs Standard Control Organisation (CDSCO) has recently flagged over 50 drugs as “not of standard quality” (NSQ). This alarming revelation has significant implications for public health and safety. Here are the key points you need to know:
- Scope of the Issue: The CDSCO identified over 50 drugs, including widely used medications like Paracetamol and Pantoprazole, as sub-standard.
- Types of Medications Affected: The list includes a variety of drugs such as calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines.
- Specific Drugs Highlighted: Notable mentions include Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd, and calcium and vitamin D3 tablets from Pure & Cure Healthcare Pvt. Ltd.
- Geographical Spread: The sub-standard drugs were produced in various regions, including Himachal Pradesh, Hyderabad, Waghodia, Vadodara, Andhra Pradesh, and Indore.
- Pharmaceutical Companies Involved: Companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), and Meg Lifesciences were among those flagged.
- Industry Response: Some pharmaceutical companies have denied responsibility, claiming that the flagged drugs are spurious and not manufactured by them.
- Regulatory Actions: The CDSCO conducts monthly random sampling to ensure drug quality, and this report is part of their ongoing efforts to maintain high standards.
- Public Health Concerns: The failure of commonly used drugs like Paracetamol to meet quality standards raises significant public health concerns, especially for medications used for pain and fever relief.
- Historical Context: This is not the first time the CDSCO has flagged sub-standard drugs. Previous reports have also highlighted similar issues, indicating a persistent problem in the pharmaceutical industry.
- Consumer Awareness: It is crucial for consumers to stay informed about the quality of medications they use and to report any adverse effects to healthcare providers immediately.
-
Gujarat Pipavav stock drops 5% after Q2 business update disappoints
Gujarat Pipavav’s Q2 total container volumes went down 17 percent on year to 179,000 TEUs in the July-September period as against 216,000 TEUs a year ago. Dry bulk volumes …
-
Reliance Power stock crashes to 5% lower circuit, still in overbought zone
Reliance Power shares hit a 5 percent lower circuit for the third session in a row amid profit-booking, following a strong 60 perent surge last month after the company …
-
Buy SignatureGlobal India; target of Rs 1905: ICICI Securities
ICICI Securities is bullish on SignatureGlobal India recommended buy rating on the stock with a target price of Rs 1905 in its research report dated October 07, 2024.
-
Gainers & losers: Stocks and sectors that moved the most on October 7
Benchmark indices ended the day in the red for the sixth straight session, albeit off the day’s lows. At close, the Sensex was down 638.45 points or 0.78 percent …
-
Hero Motors withdraws DRHP for Rs 900 crore public issue
The public issue of Hero Motors – the flagship auto components company of Hero Motors Company (HMC) Group – was proposed to be a combination of fresh issue as well …
-
Ahead of polls, BJP promises NRC in Jharkhand
“This election is to save the state. The demography of the state is changing due to infiltration from Bangladesh,” Chouhan said. “Post the elections, the citizenship register will be …